Biology Reference
In-Depth Information
220. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2',2'-
difluorodeoxycytidine 5'-triphosphate: a mechanism of self-
potentiation.
Cancer Res
1992;52:533
239. Gmeiner WH, Yu S, Pon RT, Pourquier P, Pommier Y. Structural
basis for topoisomerase I inhibition by nucleoside analogs.
Nucleosides Nucleotides Nucleic Acids
2003;22:653
9.
221. Weinstein HJ, Griffin TW, Feeney J, Cohen HJ, Propper RD,
Sallan SE. Pharmacokinetics of continuous intravenous and subcu-
taneous infusions of cytosine arabinoside.
Blood
1982;59:1351
e
8.
240. Sch¨fer A, Schomacher L, Barreto G, D¨derlein G, Niehrs C.
Gemcitabine functions epigenetically by inhibiting repair medi-
ated DNA demethylation.
PloS One
2010;5:e14060.
241. Issa JP. CpG island methylator phenotypes in cancer.
Nat Rev
Drug Discov
2004;4:988
e
3.
222. Ho DH, Frei E. Clinical pharmacology of 1-beta-d-arabinofur-
anosyl cytosine.
Clin Pharmacol Ther
1971;12:944
e
54.
223. Capizzi RL, Yang JL, Cheng E, et al. Alteration of the pharma-
cokinetics of high-dose ara-C by its metabolite, high ara-U in
patients with acute leukemia.
J Clin Oncol
1983;1:763
e
93.
242. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of
hMLH1 by epigenetic gene silencing, a novel mechanism causing
human MSI cancers.
Proc Natl Acad Sci USA
1988;95:8698
e
71.
224. Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-
CTP accumulation during high-dose ara-C therapy: pharmaco-
logic rationale for intermediate-dose ara-C.
Semin Oncol
1987;14:
159
e
702.
e
243. Oki Y, Aoki E, Issa JP. Decitabine
bedside to bench.
Crit Rev
e
52.
244. Poveda A. Gemcitabine in patients with ovarian cancer.
Cancer
Treat Rev
2005;31:S29
Oncol Hematol
2007;61:140
e
66.
225. Liliemark JO, Plunkett W, Dixon DO. Relationship of 1-beta-D-
arabinofuranosylcytosine in plasma to 1-beta-D-arabinofur-
anosylcytosine 5'-triphosphate levels in leukemic cells during
treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
Cancer Res
1985;45:5952
e
37.
245. Tepel J, Kruse ML, Kapischke M, et al. Adjuvant treatment of
pancreatic carcinoma in a clinically adapted mouse resection
model.
Pancreatology
2006;6:240
e
7.
246. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of
recent advances.
Expert Opin Invest Drugs
2006;15:1395
e
7.
226. Someya H, Shaddix SC, Tiwari KN, Secrist 3rd JA, Parker WB.
Phosphorylation of 4'-thio-beta-D-arabinofuranosylcytosine and
its analogs by human deoxycytidine kinase.
J Pharmacol Exp Ther
2003;304:1314
410.
247. Silvestris N, Cinieri S, La Torre I, et al. Role of gemcitabine in
metastatic breast cancer patients: a short review.
Breast
2008;17:
220
e
e
6.
248. Lorusso D, Ferrandina G, Fruscella E, Marini L, Adamo V,
Scambia G. Gemcitabine in epithelial ovarian cancer treatment:
current role and future perspectives.
Int J Gynecol Cancer
2005;
15:1002
e
22.
227. Dumontet C, Fabianowska-Majewska K, Mantincic D, et al.
Common resistance mechanisms to deoxynucleoside analogues
in variants of the human erythroleukaemic line K562.
Br J Hae-
matol
1999;106:78
e
13.
249. Bookman MA. Gemcitabine monotherapy in recurrent ovarian
cancer: from the bench to the clinic.
Int J Gynecol Cancer
2005;
15:12
e
85.
228. Major PP, Egan EM, Beardsley GP, Minden MD, Kufe DW.
Lethality of human myeloblasts correlates with the incorporation
of arabinofuranosylcytosine into DNA.
Proc Natl Acad Sci USA
1981;78:3235
e
7.
250. Richardson DL, Backes FJ, Seamon LG, et al. Combination gem-
citabine, platinum, bevacizumab for the treatment of recurrent
ovarian cancer.
Gynecol Oncol
2008;111:461
e
9.
229. Major PP, Egan EM, Herrick DJ, Kufe DW. Effect of ARA-C
incorporation on deoxyribonucleic acid synthesis in cells.
Biochem
Pharmacol
1982;31:2937
e
6.
251. Ozols RF. Gemcitabine and carboplatin in second-line ovarian
cancer.
Semin Oncol
2005;32:S4
e
8.
252. Sehouli J. Review of gemcitabine-based combinations for plat-
inum-resistant ovarian cancer.
Int J Gynecol Cancer
2005;15:23
40.
230. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of
2', 2'-difluorodeoxycytidine on DNA synthesis.
Cancer Res
1991;
51:6110
e
e
30.
253. Hoff PM, Fuchs CS. The experience with oxaliplatin in the
treatment of upper gastrointestinal carcinomas.
Semin Oncol
2003;30:54
e
7.
231. Jiang HY, Hickey RJ, Abdel-Aziz W, Malkas LH. Effects of gem-
citabine and araC on in vitro DNA synthesis mediated by the
human breast cell DNA synthesome.
Cancer Chemother Pharmacol
2000;45:320
e
61.
254. Chua YJ, Cunningham D. Chemotherapy for advanced pancre-
atic cancer.
Best Pract Res Clin Gastroenterol
2006;20:327
e
48.
255. Teusink AC, Hall PD. Toxicities of gemcitabine in patients with
severe hepatic dysfunction.
Ann Pharmacother
2010;44:750
8.
232. Richardson KA, Vega TP, Richardson FC, et al. Polymerization of
the triphosphates of AraC, 2',2'-difluorodeoxycytidine (dFdC)
and OSI-7836 (T-araC) by human DNA polymerase alpha and
DNA primase.
Biochem Pharmacol
2004;68:2337
e
e
4.
256. Meliani E, Lapini A, Serni S, Corvino C, Carini M. Gemcitabine
plus cisplatin in adjuvant regimen for bladder cancer. Toxicity
evaluation.
Urol Int
2003;71:37
e
46.
233. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of
gemcitabine.
Anticancer Drugs
1995;6:7
e
40.
257. PetersGJ, vanderWilt CL, vanMoorsel CJ, Kroep JR, BergmanAM,
Ackland SP. Basis for effective combination cancer chemotherapy
with antimetabolites.
Pharmacol Ther
2000;87:227
e
13.
234. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of
2',2'-difluorodeoxycytidine on DNA synthesis.
Cancer Res
1991;51:6110
e
53.
258. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin
(GEMOX) in gemcitabine refractory advanced pancreatic
adenocarcinoma: a phase II study.
Br J Cancer
2006;94:481
e
7.
235 Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide
reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Mol
Pharmacol
1990;38:567
e
5.
259. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In
vitro cross-resistance and collateral sensitivity in seven resistant
small-cell lung cancer cell lines: preclinical identification of
suitable drug partners to taxotere, taxol, topotecan and gemci-
tabin.
Br J Cancer
1997;75:869
e
72.
236. Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine:
a modulator of intracellular nucleotide and deoxynucleotide
metabolism.
Semin Oncol
1995;22:11
e
8.
237. Xu YZ, Plunkett W. Modulation of deoxycytidylate deaminase in
intact human leukemia cells. Action of 2',2'-difluorodeox-
ycytidine.
Biochem Pharmacol
1992;44:1819
e
77.
260. Chen YW, Cleaver JE, Hatahet Z, et al. DNA polymerase eta
activity and translocation is regulated by phosphorylation.
Proc
Natl Acad Sci USA
2008;105:16578
e
27.
238. Gandhi V, Mineishi S, Huang P, et al. Cytotoxicity, metabolism,
mechanisms of action of 2', 2'-difluorodeoxyguanosine in
Chinese hamster ovary cells.
Cancer Res
1995;55:1517
e
83.
261. Rockwell S. Experimental radiotherapy: a brief history.
Radiat Res
1988;150:S157
e
e
24.
e
69.
